Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00797108 · ClinicalTrials.gov registry record · Phase 2

A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization

A Phase 2 study of Pneumonia, Bacterial, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
35
Enrollment target
20
Study locations

NCT00797108 is a Phase 2 study of Pneumonia, Bacterial that has completed, run by Pfizer. The registered enrollment target is 35 participants, below the 1,344-participant average among 7 other Pneumonia, Bacterial trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00797108, a Phase 2 study of Pneumonia, Bacterial, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
35 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to test if intravenous sulopenem and an oral drug, PF-03709270 are safe and effective in patients that are hospitalized with community acquired pneumonia.

Conditions Studied

Interventions

  • DRUG sulopenem and PF-03709270
  • DRUG Sulopenem and PF-03709270
  • DRUG Ceftriaxone and amoxicillin/clavulanate

Study Locations (20)

California

  • eStudySite, Inc. - Chula Vista
  • Sharp Chula Vista Medical Center - Chula Vista
  • eStudySite, Inc. - Oceanside
  • Tri-City Medical Center - Oceanside

Other

  • Oddzial Chorob Wewnetrznych i Gastroenterologii - Bialystok
  • Oddzial Chorob Pluc - Brzesko
  • Kliniczny Oddzial Gruzlicy i Chorob Pluc - Krakow
  • Oddzial Kliniczny Pulmonologii i Alergologii - Lodz

Ohio

  • Summa Health System - Akron
  • Summa Health System - Akron
  • Summa Health System - Akron

Ontario

  • Hamilton Health Sciences - General Site - Hamilton
  • Hamilton Health Sciences- McMaster Site - Hamilton
  • Hamilton Health Sciences - Henderson Site - Hamilton

Illinois

  • Medical Arts Associates, Ltd - Moline
  • Trinity Medical Center - Rock Island

Utah

  • Utah Valley Pulmonary Clinic - Provo
  • Utah Valley Regional Medical Center - Provo

Minnesota

  • Infectious Disease Minneapolis Limited - Minneapolis

Queensland

  • Infection Management Services, Building 17, Level 1 - Brisbane

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2009-01
Est. Completion 2009-06
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT00797108

The ClinicalTrials.gov registry entry for NCT00797108 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,344-participant average among 7 other Pneumonia, Bacterial trials with a reported enrollment target (97% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pneumonia, Bacterial appearing as the primary indexed condition, and to 3 interventions - of which sulopenem and PF-03709270 is the first listed.

NCT00797108 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Other, Ohio.

Frequently Asked Questions

What is clinical trial NCT00797108 about?

NCT00797108 is a clinical study titled "A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization". The purpose of this study is to test if intravenous sulopenem and an oral drug, PF-03709270 are safe and effective in patients that are hospitalized with community acquired pneumonia.

What is the current status of trial NCT00797108?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2009-01. Estimated completion is 2009-06.

What conditions does trial NCT00797108 study?

This clinical trial studies the following conditions: Pneumonia, Bacterial.

What interventions are being tested in trial NCT00797108?

The interventions under investigation include: sulopenem and PF-03709270 (DRUG), Sulopenem and PF-03709270 (DRUG), Ceftriaxone and amoxicillin/clavulanate (DRUG).

Who is sponsoring clinical trial NCT00797108?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00797108 being conducted?

This trial has 20 study locations across California, Illinois, Minnesota, Ohio, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pneumonia, Bacterial

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.